Dr. Richard Heinzl, Physician, Humanitarian, Entrepreneur and Author, Appointed to Asep Inc.’s Board of Directors

VANCOUVER, BC, September 29, 2022 /CNW/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce the appointment of Dr. Richard Heinzl to the company’s Management Board with immediate effect.

Also Read :  Barriers to Black entrepreneurship widen the wealth gap

dr Heinzl is a physician, humanist, entrepreneur and author whose current focus is on genomics, artificial intelligence and global healthcare. Based in new York and Torontohe is currently CEO of My Next Health Inc., a next-generation functional genomics company.

At the beginning of his career, Dr. Heinzl Founder of the Canadian section of Médecins Sans Frontières/Doctors Without Borders (MSF Canada), winner of the 1999 Nobel Peace Prize. Most recently, he was Global Medical Director for WorldCare Inc., a Boston-based, Harvard-affiliated virtual medicine company. He graduated in from McMaster University Michael G. DeGroote School of Medicine and completed postgraduate degrees related to global health Harvard University and the University of Oxford. He is Emeritus Fellow of the American College of Preventive Medicine. His work and travels have taken him to over 80 countries and he speaks in many countries North America and abroad. In 2000 he received an honorary doctorate (LLD) from his alma mater. McMaster University and was named one of the “Hundred People Making a Difference”. Canada by Penguin Books. in the September 2016He received the Harvard TH Chan School of Public Health Alumni Award of Merit, the school’s highest honor.

dr Heinzl stated: “I am very honored to be part of the Asep team Bob Hancocks visionary scientific leadership. It’s really exciting to see how biotechnologies have tremendous potential to change the paradigm of human healthcare.”

“Having a world-class physician and entrepreneur on our board will support our mission to address unmet medical needs in large unmet markets related to antibiotic failure,” he said Robert EW Hancock, CEO and co-founder of Asep. “Richard will bring a strong medical and global perspective to the board.”


Asep Medical Inc. (asepmedical.com) is dedicated to addressing antibiotic failure by developing novel solutions to a significant unmet medical need. The Company is an amalgamation of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.), both in late-stage development of proprietary diagnostic tools that enable early and timely detection of severe sepsis, as well as broad-spectrum therapeutic agents against multidrug-resistant biofilm infections.

Sepset Biosciences Inc. (sepset.ca) is developing diagnostic technology that includes a patient’s gene expression signature that predicts severe sepsis, one of the significant diseases leading to antibiotic failure as antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for almost 20% of all deaths on the planet. The SepsetHE The test is a blood-based gene expression test that is easy to perform and has results available in about an hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in that it enables the diagnosis of severe sepsis within 1-2 hours after the initial clinical presentation (ie, in the emergency department), while other diagnostics only provide a diagnosis after 24-36 hours . Asep Inc. believes this will allow physicians to make important early decisions regarding appropriate therapies and reduce overall morbidity and mortality from sepsis.

ABT Innovations Inc. (abtinnovations.ca) peptide technology covers a broad spectrum of therapeutic applications including bacterial biofilm infections (medical device infections, chronic infections, pulmonary, bladder, wound, dental, skin, throat, nose and throat infections, sinusitis). , orthopedics, etc.), anti-inflammatory drugs, anti-infective immunomodulators and vaccine adjuvants.


This press release contains certain “forward-looking statements” which are defined as such under applicable securities laws. Forward-looking statements are often identified by words such as “anticipate”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”. “, “potential”, “proposed”, “positioned” and other similar words or statements that certain events or conditions “may” or “will” occur. These statements include, but are not limited to, the completion of successful clinical testing of our sepsis diagnostic test and intended application for regulatory approval; and conducting preclinical studies of our lead therapeutic with the expectation that this will lead to accelerated clinical trials. Various assumptions have been used in order to draw conclusions or make predictions contained in the forward-looking statements contained in this press release. Forward-looking statements are based on the opinions and estimates of management at the time the statements are made and are subject to a variety of risks (including the risk factors discussed in Asep Medical Inc.’s prospectus). November 9, 2021), which can be found under the Company’s profile at www.sedar.com, uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Asep Medical Inc. undertakes no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

SOURCE ASEP Medical Holdings Inc.

For more information: Chris Dallin, Director of Marketing, Asep Medical Holdings Inc., E. [email protected]T. +1 (604) 362.3654